Syntax Bio is a synthetic biology company focused on making cell programming faster, more reliable, and scalable for next-generation therapies. The company develops CRISPR-based technologies that precisely control when and how genes are activated in human cells, replacing slow and variable manual differentiation methods. Its flagship platform, Cellgorithm, encodes developmental instructions directly into DNA, enabling stem cells to be guided into specific cell types in days to weeks rather than months. By bringing software-like precision to cell engineering, Syntax Bio aims to accelerate regenerative medicine research, reduce manufacturing costs, and support the development of new cell-based treatments in partnership with biopharmaceutical companies.